Azithromycin paradox in the treatment of cystic fibrosis airway disease

Papers of special note have been highlighted as:   of interest ▪▪ of considerable interest

Bibliography

• 1  Saiman L, Anstead M, Mayer-Hamblett N et al.: Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA303(17),1707–1715 (2010).
  Medline CASGoogle Scholar
• 2  Saiman L, Marshall BC, Mayer-Hamblett N et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA290(13),1749–1756 (2003).▪▪ Randomized, placebo-controlled trial of azithromycin on cystic fibrosis (CF) patients colonized with Pseudomonas aeruginosa. This earlier study complements the study reviewed here.
  Medline CASGoogle Scholar
• 3  Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax57(3),212–216 (2002).
  Medline CASGoogle Scholar
• 4  Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J: Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax61(10),895–902 (2006).
  Medline CASGoogle Scholar
• 5  Tramper-Stranders GA, Wolfs TFW, Fleer A, Kimpen JLL, van der Ent CK: Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr. Infect. Dis. J.26(1),8–12 (2007).▪▪ Long-term study on the benefits of macrolide therapy for CF patients colonized by Staphylococcus aureus. This study showed that the benefits were transient and after about 1 year the rate of lung function decline returned to the pretreatment rate. This was independent of macrolide resistance in the S. aureus.
  MedlineGoogle Scholar
• 6  Florescu DF, Murphy PJ, Kalil AC: Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm. Pharmacol. Ther.22(6),467–472 (2009).
  Medline CASGoogle Scholar
• 7  Main E, Prasad A, Schans C: Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst. Rev.(1),CD002011 (2005).
  MedlineGoogle Scholar
• 8  Fuchs HJ, Borowitz DS, Christiansen DH et al.: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N. Engl. J. Med.331(10),637–642 (1994).
  Medline CASGoogle Scholar
• 9  Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med.354(3),241–250 (2006).
  Medline CASGoogle Scholar
• 10  Koyama H, Geddes DM: Erythromycin and diffuse panbronchiolitis. Thorax52(10),915–918 (1997).▪ Initial study demonstrating the dramatic effects of macrolides on diffuse panbronchiolitis.
  Medline CASGoogle Scholar
• 11  Tateda K, Ishii Y, Matsumoto T et al.: Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother.40(10),2271–2275 (1996).
  Medline CASGoogle Scholar
• 12  Imamura Y, Higashiyama Y, Tomono K et al.: Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother.49(4),1377–1380 (2005).
  Medline CASGoogle Scholar
• 13  Baumann U, King M, App EM et al.: Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J.11(2),151–155 (2004).
  MedlineGoogle Scholar
• 14  Giamarellos-Bourboulis EJ: Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int. J. Antimicrob. Agents31(1),12–20 (2008).
  Medline CASGoogle Scholar
• 15  Saiman L, Chen Y, Gabriel PS, Knirsch C: Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother.46(4),1105–1107 (2002).
  Medline CASGoogle Scholar
• 16  Howe RA, Spencer RC: Macrolides for the treatment of Pseudomonas aeruginosa infections? J. Antimicrob. Chemother.40(2),153–155 (1997).
  Medline CASGoogle Scholar
• 17  Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M: Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother.44(10),2869–2872 (2000).
  Medline CASGoogle Scholar
• 18  Hirakata Y, Kaku M, Mizukane R et al.: Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob. Agents Chemother.36(9),1922–1927 (1992).
  Medline CASGoogle Scholar
• 19  Kita E, Sawaki M, Oku D et al.: Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J. Antimicrob. Chemother.27(3),273–284 (1991).
  Medline CASGoogle Scholar
• 20  Mizukane R, Hirakata Y, Kaku M et al.: Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. Antimicrob. Agents Chemother.38(3),528–533 (1994).
  Medline CASGoogle Scholar
• 21  Molinari G, Guzmán CA, Pesce A, Schito GC: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother.31(5),681–688 (1993).
  Medline CASGoogle Scholar
• 22  Wagner T, Soong G, Sokol S, Saiman L, Prince A: Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest128(2),912–919 (2005).
  Medline CASGoogle Scholar
• 23  Nagino K, Kobayashi H: Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin. Microbiol. Infect.3(4),432–439 (1997).
  Medline CASGoogle Scholar
• 24  Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M: The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosain vitro. Chemotherapy42(3),186–191 (1996).
  Medline CASGoogle Scholar
• 25  Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T: Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob. Agents Chemother.37(9),1749–1755 (1993).
  Medline CASGoogle Scholar
• 26  Ichimiya T, Yamasaki T, Nasu M: In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J. Antimicrob. Chemother.34(3),331–341 (1994).
  Medline CASGoogle Scholar
• 27  Kobayashi H: Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am. J. Med.99(6A),S26–S30 (1995).
  Google Scholar
• 28  Tamaoki J: The effects of macrolides on inflammatory cells. Chest125(2 Suppl.),S41–S50 (2004).
  Medline CASGoogle Scholar
• 29  Tsai WC, Rodriguez ML, Young KS et al.: Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am. J. Respir. Crit. Care Med.170(12),1331–1339 (2004).
  MedlineGoogle Scholar
• 30  Takizawa H, Desaki M, Ohtoshi T et al.: Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Respir. Crit. Care Med.156(1),266–271 (1997).
  Medline CASGoogle Scholar
• 31  Khan AA, Slifer TR, Araujo FG, Remington JS: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int. J. Antimicrob. Agents11(2),121–132 (1999).
  Medline CASGoogle Scholar
• 32  Abe S, Nakamura H, Inoue S et al.: Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol.22(1),51–60 (2000).
  Medline CASGoogle Scholar
• 33  Morikawa K, Watabe H, Araake M, Morikawa S: Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother.40(6),1366–1370 (1996).
  Medline CASGoogle Scholar
• 34  Gant TW, O’Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS: In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol.133(2),269–276 (1995).
  Medline CASGoogle Scholar
• 35  Jaffé A, Francis J, Rosenthal M, Bush A: Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet351(9100),420 (1998).
  Medline CASGoogle Scholar
• 36  Equi A, Balfour-Lynn IM, Bush A, Rosenthal M: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet360(9338),978–984 (2002).▪ Highlights the heterogeneity of response to macrolide therapy in different patients. This presentation of the data emphasizes that more refined stratification of CF patients should be performed.
  Medline CASGoogle Scholar
• 37  Ramsey BW, Pepe MS, Quan JM et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis inhaled tobramycin study group. N. Engl. J. Med.340(1),23–30 (1999).
  Medline CASGoogle Scholar
• 38  Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Group MS: Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med.172(8),1008–1012 (2005).
  MedlineGoogle Scholar
• 39  Equi AC, Davies JC, Painter H et al.: Exploring the mechanisms of macrolides in cystic fibrosis. Respir. Med.100(4),687–697 (2006).
  MedlineGoogle Scholar
• 40  Sibley CD, Rabin H, Surette MG: Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol.1(1),53–61 (2006).
  CASGoogle Scholar
• 41  Duan K, Dammel C, Stein J, Rabin H, Surette MG: Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol. Microbiol.50(5),1477–1491 (2003).
  Medline CASGoogle Scholar
• 42  Sibley CD, Duan K, Fischer C et al.: Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog.4(10),e1000184 (2008).▪▪ Demonstrates (in an animal model) that many organisms considered to be avirulent normal microbiota isolated from CF sputum samples are potentially pathogenic or enhance the virulence of P. aeruginosa in mixed infections.
  MedlineGoogle Scholar
• 43  Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG: A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl Acad. Sci. USA105(39),15070–15075 (2008).▪▪ Highlights a role for the Streptococcus milleri group in acute exacerbations and demonstrates that common pathogens can be overlooked by standard CF microbiology practices.
  Medline CASGoogle Scholar
• 44  Ergin A, Ercis S, Celik GH: Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures. J. Antimicrob. Chemother.57(1),139–141 (2006).
  Medline CASGoogle Scholar
• 45  Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH: Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY antimicrobial surveillance program (1997–2000). Diagn. Microbiol. Infect. Dis.43(2),157–162 (2002).
  Medline CASGoogle Scholar
• 46  Asmah N, Eberspächer B, Regnath T, Arvand M: Prevalence of erythromycin and clindamycin resistance among clinical isolates of the Streptococcus anginosus group in Germany. J. Med. Microbiol.58(Pt 2),222–227 (2009).
  Medline CASGoogle Scholar
• 47  Seppälä H, Haanperä M, Al-Juhaish M, Järvinen H, Jalava J, Huovinen P: Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J. Antimicrob. Chemother.52(4),636–644 (2003).
  MedlineGoogle Scholar
• 48  Malhotra-Kumar S, Lammens C, Martel A et al.: Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium. J. Antimicrob. Chemother.53(2),271–276 (2004).
  Medline CASGoogle Scholar
• 49  Aracil B, Minambres M, Oteo J, Torres C, Gómez-Garcés JL, Alós JI: High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J. Antimicrob. Chemother.48(4),592–594 (2001).
  Medline CASGoogle Scholar
• 50  Eisenblätter M, Klaus C, Pletz MWR et al.: Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers. Eur. J. Clin. Microbiol. Infect. Dis.27(11),1087–1092 (2008).
  Medline CASGoogle Scholar
• 51  Tazumi A, Maeda Y, Goldsmith CE et al.: Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J. Antimicrob. Chemother.64(3),501–506 (2009).▪ Reports the prevalence of macrolide resistance in commensal Streptococcus (viridans group) isolated from the airways of CF patients, and demonstrates high rates of resistance from patients who have received macrolides.
  Medline CASGoogle Scholar
• 52– Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG: Macrolide and clindamycin resistance in Streptococcus milleri group isolates from cystic fibrosis airways. Antimicrob. Agents Chemother.54(7),2823–2829 (2010).▪ Reports the prevalence of antibiotic resistance in Streptococcus milleri group isolates from the airways of CF patients, and demonstrates high rates of macrolide resistance in patients who have received azithromycin.
  Medline CASGoogle Scholar